SNYR - Synergy CHC Corp. Market Value to Book Value Ratio

synergychc.com (SNYR) - corporate logo

Synergy CHC Corp (SNYR) holds assets in the beauty and health segment, where revenue stability is based on consistent retail demand. However, the company's profits are under pressure due to rising online promotion costs and competition with market behemoths, with the current figure standing at -0.04. The stock's price chart complements the data on this health-brand holding, which is attracting creative specialists to develop its e-commerce operations.

synergychc.com (SNYR) - Market Value to Book Value from 10/24/2024 to 10/03/2026
Manufactured product of synergychc.com

The mvsbcap_co ratio determines the market price premium over the net asset value, revealing the gap between book valuation and investor expectations. Values above one indicate overvaluation or confidence in future growth. The price-to-book dynamics on GURU.Markets help identify trend reversal points. For Synergy CHC Corp (SNYR), this metric reflects the market valuation of the effectiveness of its strategy to acquire niche brands. The indicator demonstrates the extent to which market capitalization outpaces the value of acquired assets in the beauty and nutrition sector.

Competitor analysis

Haleon plc (HLN) - Market Value to Book Value Ratio|kenvue.com - Market Value to Book Value|Market Value to Book Value Ratio Verona Pharma|Jyong Biotech Limited - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio LGND|AMRX (Amneal Corp) - Market Value to Book Value|Market Capitalization to Book Value Ratio PRGO (Perrigo Company plc)|Market Capitalization to Book Value Ratio alvotech.com ALVO|LQDA - Market Value to Book Value Ratio|Market Value to Book Value GLPG (Galapagos N.V.)|ANI Pharma (ANIP) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Afrezza|AMPH (Amphastar Pharmaceuticals) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio pacira.com|Market Cap to Net Assets Ratio SPRY (ARS Pharmaceuticals, Inc.)|TBPH (Theravance Biopharma Inc) - Market Value to Book Value|Market Value to Book Value Ratio Aquestive Pharma AQST|scPharmaceuticals, Inc. (SCPH) - Market-to-Book Ratio|TECX: Market Cap to Net Assets Ratio|tonixpharma.com - Market Cap to Book Value Multiple|SXTC: Market Capitalization to Book Value Ratio|Eupraxia Pharmaceuticals Inc. - Market Value to Book Value|BHST (BioHarvest) - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Invizyne EXOZ|Market Value to Book Value Ratio Oramed Pharmaceuticals (ORMP)|ENTX (enterabio.com) - Market Value to Book Value|Market Value to Book Value Ratio MindWalk Holdings Inc. HYFT|Market Capitalization to Book Value ABVC BioPharma Inc. (ABVC)|CPIX: Market Cap to Net Assets Ratio|Market-to-Book Ratio Quantum BioPharma Corp|FibroGen, Inc. (FGEN) - Market Value to Book Value Ratio|Capitalization to Book Value Ratio TELO|RANI (Rani Therapeutics Holdings) - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Rallybio Corp. RLYB|Market Value to Book Value Ratio Lexaria Bioscience (LEXX)|PULM (Pulmatrix Corporation) - Market Value to Book Value|Market Capitalization to Book Value Ratio PTHL (Pheton Holdings)|Market Value to Equity Ratio Aptorum Group Ltd|LYRA: Market Cap to Net Assets Ratio|Market-to-Book Ratio impactbiomedinc.com|TNFA (tnfpharma.com) - Market Cap to Net Assets Ratio|cbdMD - Market Value to Book Value|PRFX (PainReform Ltd.) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Auris Medical (CYTO)|Market Capitalization to Book Value Ratio LIPO|OPTN (OptiNose Inc) - Market Value to Book Value|Market Capitalization to Book Value Ratio PIRS (Pieris)|PROC - Market Cap to Net Assets Ratio|PTPI: Market Cap to Net Assets Ratio|Market Value to Book Value QLI (qlsyy.net)|SLRN: Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio TFF Pharmaceuticals Inc.